GVR Report cover Mammalian Polyclonal IgG Antibody Market Size, Share & Trends Report

Mammalian Polyclonal IgG Antibody Market Size, Share & Trends Analysis Report By Type (Mouse, Rabbit), By Product (Cardiac, Metabolic), By Application, By End Use, By Region, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-615-8
  • Number of Pages: 109
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Report Overview

The global mammalian polyclonal IgG antibody market size to be valued at USD 1.21 billion by 2025 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% during the forecast period. Advantages over other forms of antibodies, increasing R&D investments, and rising adoption of novel diagnostic procedures are major factors boosting the market growth.

Mammalian Polyclonal IgG Antibody Market size, by product

Polyclonal antibodies are often the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these antibodies does not require skilled professionals and large batches can be produced as per client requirements.

The rise in investments by biotechnology and pharmaceutical companies has led to technological advancements in the process of antibody production. These advancements have increased the product demand, thereby augmenting the market. In recent years, biopharma companies have been willing to invest in the development of new and efficient antibodies for QC purposes.

For instance, R&D investments by the top 10 biotech companies increased from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, accounting for a 13% increase. Mammalian polyclonal IgG antibodies are being increasingly used in the diagnosis of chronic diseases, such as cancer, diabetes, autoimmune diseases, and metabolic diseases.

The rising use of biomarkers for accurate and rapid diagnosis is further boosting the global market. CD20 biomarkers for diagnosis of B-cell lymphoma and leukemia are being increasingly used by clinicians, leading to an increase in demand for these products.

Mammalian Polyclonal IgG Antibody Market Trends

The rising popularity of standard laboratory tests such as microarray assays, western blot analysis, immunohistochemical, and cell imaging, as well the rising occurrence of chronic diseases like cancer, among others are driving the expansion of the market. Furthermore, the market is witnessing a surge in investments by pharmaceuticals and biotechnology companies.

Growth in healthcare infrastructure, research and development, and investments have a positive impact on the mammalian polyclonal IgG antibody demand. Moreover, in the forecast period, the increased utilization of biomarkers for accuracy is anticipated to create lucrative growth opportunities for all market players.

The market is projected to be hampered by the stringent regulations related to the approval and use of biomarkers and the lack of awareness about the use of products.

Product Insights

Based on product type, the mammalian IgG polyclonal antibody market is segmented into cardiac, metabolic, renal, and other biomarkers. The rising prevalence of Cardiovascular Diseases (CVDs) due to unhealthy eating habits, sedentary lifestyles, and lack of physical activity is driving the cardiac biomarkers segment. Metabolic biomarkers are used for testing a wide range of diseases. The segment is thus projected to expand at the highest CAGR of 5.5% during the forecast period.

The increasing use of metabolic biomarkers for the diagnosis of diabetes is anticipated to propel its growth. The estimates from the International Diabetes Federation indicate that over 425 million people were suffering from diabetes globally in 2017. Type II diabetes is the most common type of diabetes and 90% of the affected population suffers from this type. Globally increasing cases of cancer are also anticipated to fuel the segment growth in the near future. Other biomarkers taken into the consideration in the study are cancer, and autoimmune biomarkers.

Type Insights

Based on animal hosts, the market is segmented into goat, rabbit, horse, mouse, and others. The mouse segment is anticipated to exhibit the highest CAGR owing to the predominant use of these animals for polyclonal antibody production. Antibody and antigen structural forms in humans and mice are similar, which is the prime reason for their increasing usage in research. Thus, the mouse segment is expected to generate significant revenue by 2025.

Rabbit antibodies, due to high specificity, showcase an enhanced immune response to small epitopes, facilitating increased recognition during disease diagnosis. The large variety of high-affinity antibodies produced by rabbits aids in finding immunoglobulins that have a wide range of applications, such as immunohistochemistry, ELISA, Western Blotting, immunocytochemistry, and others. This is anticipated to have a positive impact on the segment growth.

Mammalian Polyclonal IgG Antibody Market share, by type

When a large volume of antisera is required, antibodies are generally harvested from large animals, such as horses. Horses are also relatively better hosts for antibody production for several diseases including influenza, tuberculosis, Crohn’s disease, and asthma. Horse antisera have also been used for the treatment of tetanus, snake bites, and diphtheria among others. Mice are extremely useful for research on complex diseases due to their similarities with humans. Thus, research on hypertension and atherosclerosis is mainly conducted using mice as host species. Due to all these factors, this segment is also anticipated to gain considerable market share in the near future.

Application Insights

On the basis of application, the market is segmented into ELISA, immunoturbidometry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting. Western blotting held the largest revenue in the year 2017, owing to its sensitivity and specificity. The use of Western Blotting facilitates disease detection with few antibodies, considerably reducing laboratory costs. The protein specificity of these tests is another key factor responsible for its increased demand.

However, the ELISA segment is anticipated to witness the highest CAGR of 5.8% over the forecast years due to its predominant use in antibody-related tests. It is the most often used test due to its accurate diagnosis of diseases, such as AIDS, Lyme disease, syphilis, pernicious anemia, and viral infections. The immunohistochemistry, used in tumor detection, is expected to account for a significant market share in the near future.

This is mainly due to its higher specificity, which aids in the identification of structural differences, often seen in tumor cells. Rising adoption and advancements in equipment are also likely to propel segment growth.

End-Use Insights

Based on end-use, the market is divided into hospitals, diagnostic centers, and academic and research centers. Rising disease prevalence and increasing use of biomarkers for testing and diagnostic purposes are anticipated to influence the diagnostic centers segment growth. It held the largest market share owing to the high usage of polyclonal antibodies for disease diagnosis. According to the World Health Organization (WHO), the incidence of tropical diseases, such as malaria, chikungunya, dengue, and yellow fever, has increased significantly, driving the demand for polyclonal antibodies.

Thus, the diagnostic centers segment is anticipated to gain a significant market share during the forecast period. Academic and research centers generated significant revenue in 2017 due to the increased number of research activities on personalized medicine and improving drug efficacy. Hospitals held a considerable market share, owing to the high number of cases and diagnostic tests conducted in these settings. The rise in the number of hospitals across the globe has also led to the growth of this segment. The growing need for hospitals with advanced facilities for the detection of antigens in patient samples due to the increasing prevalence of chronic diseases will also drive the segment.

Regional Insights

North America led the market in 2017 due to the presence of well-equipped research facilities and leading companies producing antibodies in the region. Moreover, quick adoption of advanced technologies and focus on clinical research are expected to drive regional growth. Favorable reimbursement policies in the U.S. have propelled the use of polyclonal antibody techniques in the country.

The presence of government organizations, such as the CDC, has contributed to the dominance of the regional market. Rising awareness among people and increasing R&D activities are some of the key factors contributing to the growth. Furthermore, collaborative programs between U.S. and China or biomedical research and increased research funding are expected to boost the market during the study period.

Mammalian Polyclonal IgG Antibody Market Trends by Region

Asia Pacific (APAC) is anticipated to witness the highest growth during the forecast period owing to rising disposable income and the increasing prevalence of cancer and diabetes. The growing focus of leading manufacturers on strengthening their presence in the emerging countries of APAC will also augment the regional market. Moreover, high demand for regenerative medicines and government support are expected to fuel growth in APAC.

For instance, the Japanese government provides funds to Okinawa Health Biotechnology Research and Development Center, an organization that provides free research facilities to eligible biotechnology companies. Thus, rising investments by pharmaceutical and biopharmaceutical companies coupled with high disease incidences are the factors driving the APAC regional market growth.

Key Companies & Market Share Insights

The market includes a large number of global and local companies. Some of the key companies include Abcam PLC; Bio-Rad Laboratories; Thermo Fisher Scientific, Inc.; Merck KGaA; Cell Signaling Technology, Inc.; and F. Hoffman-La Roche. Most of these firms have a strong geographic presence, in terms of distribution networks and operating facilities. For instance, Abcam PLC is present in 130+ countries.

These organizations have undertaken various business strategies including M&A and strategic agreements to gain a competitive edge over other companies. For instance, in January 2018, Abcam signed an exclusive license agreement with Roche AG under which, the product portfolio of Spring Bioscience Corporation will be accessible to Abcam for research purposes. The portfolio consists of over 243 recombinant rabbit monoclonal antibodies.

Regional expansion is another strategy undertaken by most market players. For instance, in November 2015, Abcam announced the launch of its direct service in Singapore to strengthen the collaborations with research institutes and companies in the Asia Pacific region.

Recent Developments

  • In February 2022, Twist Bioscience Corporation and Abcam announced a licencing deal in which Abcam would employ an unique Twist VHH phage library for antibody discovery, development, and commercialization in diagnostic and research applications

  • In May 2022, The Qatar Genome Program (QGP) announced a collaboration with Thermo Fisher Scientific to develop a pan-Arab genotyping array, with the goal of providing a more cost-effective alternative to whole-genome sequencing and increased variety in genome-wide research

  • In June 2021, Seegene, Inc., a global pioneer in multiplex molecular diagnostics, has announced a cooperation with Bio-Rad Laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic technologies. According to the terms of the agreement, Seegene will supply diagnostic assays for use on Bio-CFX96 Rad's Dx Real-Time PCR System in the United States

Mammalian Polyclonal IgG Antibody Market Report Scope

Report Attribute


Market size value in 2020

USD 941.5 million

Revenue forecast in 2025

USD 1.2 billion

Growth Rate

CAGR of 5.1% from 2018 to 2025

Base year for estimation


Historical data

2014 - 2016

Forecast period

2018 - 2025

Quantitative units

Revenue in USD million and CAGR from 2018 to 2025

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Product, type, application, end use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

Abcam PLC; Bio-Rad Laboratories; Thermo Fisher Scientific, Inc.; Merck KGaA; Cell Signaling Technology, Inc.; F. Hoffman-La Roche

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Mammalian Polyclonal IgG Antibody Market Segmentation

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global mammalian polyclonal IgG antibody market report on the basis of type, product, application, end use, and region:

Global Mammalian Polyclonal IgG Antibody Market Segmentation

  • Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Goat

    • Rabbit

    • Horse

    • Mouse

    • Others

  • Product Outlook (Revenue, USD Million, 2014 - 2025)

    • Cardiac Markers

    • Metabolic Markers

    • Renal Markers

    • Others

  • Application Outlook (Revenue, USD Million, 2014 - 2025)

    • ELISA

    • Immunoturbidometry

    • Immunoelectrophoresis

    • Antibody Identification

    • Immunohistochemistry

    • Immunocytochemistry

    • Western Blotting

  • End Use Outlook (Revenue, USD Million, 2014 - 2025)

    • Hospitals

    • Diagnostic Centers

    • Academic and Research Institutes

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon